SKP2 and prostate carcinoma: In particular, Skp2 upregulation has been demonstrated in breast carcinoma, non-small cell lung cancer, colorectal carcinoma, gastric carcinoma, renal cell carcinoma, early esophageal squamous cell carcinoma, malignant melanoma, prostate cancer, chronic myelogenous leukemia, malignant lymphoma, and several other human cancers [62, 63].